OCUP Ocuphire: Net earnings per share growth forecast for next year

OCUP (Ocuphire Corporation) - company brandmark

Risks for Ocuphire Pharma, Inc. (OCUP) are linked to the anticipation of late-stage drug trial results for retinopathy, which supports the current EPS growth forecast for the next period. The value of -2.60 reflects the current volume of this metric. Stability is provided by Nyxol's authority in ophthalmology, while eco-friendly drug synthesis and zero-waste laboratories minimize operational threats, supporting sustainable business development.

OCUP: Ocuphire Corporation Expected earnings per share growth for next year 07/04/2022 - 10/24/2024

Ocuphire Pharma (OCUP) - metric breakdowns and financial figures

- price and consensus price forecast:
Fundamental company valuation:ocuphire.com, OCUP
Core merchandise of ocuphire.com

The stability of Ocuphire Pharma, Inc. (OCUP) depends on the commercialization of drugs for presbyopia therapy and retinal protection, which directly impacts future cash flows. This indicator assesses the expected profit dynamics for the coming year, adjusting historical data for inflationary risks and personnel costs, which allows for a forecast of the asset's real investment attractiveness through the modeled EPS growth for the next fiscal year.

Competitor analysis

ALC (Alcon Corp) - Earnings growth forecast for next year|Bausch + Lomb Corporation (BLCO) - Consensus forecast of earnings per share growth for next year|Earnings growth forecast for next year GKOS|Earnings growth forecast for next year Apellis Pharmaceuticals, Inc. (APLS)|Earnings growth forecast for next year BLTE (Belite Bio)|OCUL - Expected earnings per share growth for next year|HROW - Net earnings per share growth forecast for next year|Expected earnings per share trend next year VRDN (Viridian Therapeutics)|LENZ (LENZ Therapeutics, Inc.) - Expected earnings per share growth for next year|Oculis Holding AG - Expected earnings per share trend next year|Net earnings per share growth forecast for next year eyepointpharma.com|Earnings growth forecast for next year Kodiak Sciences Inc.|Net earnings per share growth forecast for next year Aldeyra Therapeutics Inc. (ALDX)|Net earnings per share growth forecast for next year KALA (KALA BIO)|Net earnings per share growth forecast for next year opusgtx.com IRD|Expected earnings per share trend next year OKYO|ADVM: Expected earnings per share growth for next year|Expected earnings per share trend next year OTLK (Outlook Therapeutics)|CLSD: Earnings growth forecast for next year|NovaBay Pharmaceuticals Inc. - Expected earnings per share trend next year|Net earnings per share growth forecast for next year kiorapharma.com|Expected earnings per share growth for next year Alimera Sciences (ALIM)|Net earnings per share growth forecast for next year Eyenovia Corp (EYEN)|GHSI - Expected net earnings per share growth next year|Earnings growth forecast for next year OPT (Opthea Ltd)